SU584743A3 - Способ получени производных глюкозы - Google Patents
Способ получени производных глюкозыInfo
- Publication number
- SU584743A3 SU584743A3 SU7301962273A SU1962273A SU584743A3 SU 584743 A3 SU584743 A3 SU 584743A3 SU 7301962273 A SU7301962273 A SU 7301962273A SU 1962273 A SU1962273 A SU 1962273A SU 584743 A3 SU584743 A3 SU 584743A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- glucose
- urea
- molar ratio
- added
- animals
- Prior art date
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims description 8
- 239000008103 glucose Substances 0.000 title claims description 8
- 238000000034 method Methods 0.000 title claims description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 8
- 239000004202 carbamide Substances 0.000 claims description 8
- 239000005711 Benzoic acid Substances 0.000 claims description 7
- 235000010233 benzoic acid Nutrition 0.000 claims description 7
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- -1 equal to 1: 1 Substances 0.000 claims 1
- 150000002303 glucose derivatives Chemical class 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 239000012452 mother liquor Substances 0.000 claims 1
- 230000020477 pH reduction Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 8
- 238000010171 animal model Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000002513 implantation Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 206010027146 Melanoderma Diseases 0.000 description 1
- 241000255969 Pieris brassicae Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Inorganic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES406820A ES406820A1 (es) | 1972-09-19 | 1972-09-19 | Procedimiento para la obtencion de derivados de glucosa farmacologicamente activos. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU584743A3 true SU584743A3 (ru) | 1977-12-15 |
Family
ID=8462206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU7301962273A SU584743A3 (ru) | 1972-09-19 | 1973-09-14 | Способ получени производных глюкозы |
Country Status (15)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2688689B2 (ja) * | 1992-04-22 | 1997-12-10 | 日本エヌエスシー株式会社 | コールドシール接着剤組成物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3149033A (en) * | 1961-02-06 | 1964-09-15 | Universal Drug And Res Lab Inc | Method of administering aldohexoseurea hypoglycemic compounds to animals |
-
1972
- 1972-09-19 ES ES406820A patent/ES406820A1/es not_active Expired
-
1973
- 1973-09-12 AT AT789073A patent/AT323886B/de active
- 1973-09-12 DE DE19732345917 patent/DE2345917A1/de active Pending
- 1973-09-14 CA CA180,981A patent/CA1025360A/en not_active Expired
- 1973-09-14 SU SU7301962273A patent/SU584743A3/ru active
- 1973-09-17 FR FR7333225A patent/FR2199984B1/fr not_active Expired
- 1973-09-17 DD DD173619A patent/DD109307A5/xx unknown
- 1973-09-17 ZA ZA00737345A patent/ZA737345B/xx unknown
- 1973-09-18 JP JP48105372A patent/JPS49132222A/ja active Pending
- 1973-09-18 DK DK509673AA patent/DK138727B/da unknown
- 1973-09-18 CH CH1334173A patent/CH585219A5/xx not_active IP Right Cessation
- 1973-09-18 BE BE2053067A patent/BE804960A/xx not_active IP Right Cessation
- 1973-09-18 GB GB4382973A patent/GB1440206A/en not_active Expired
- 1973-09-19 AR AR250157A patent/AR199004A1/es active
- 1973-09-19 NL NL7312925A patent/NL7312925A/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CH585219A5 (enrdf_load_stackoverflow) | 1977-02-28 |
| GB1440206A (en) | 1976-06-23 |
| BE804960A (fr) | 1974-03-18 |
| NL7312925A (enrdf_load_stackoverflow) | 1974-03-21 |
| ZA737345B (en) | 1975-04-30 |
| DD109307A5 (enrdf_load_stackoverflow) | 1974-11-05 |
| DK138727B (da) | 1978-10-23 |
| AT323886B (de) | 1975-08-11 |
| FR2199984A1 (enrdf_load_stackoverflow) | 1974-04-19 |
| AU6036873A (en) | 1975-03-20 |
| ES406820A1 (es) | 1975-10-16 |
| AR199004A1 (es) | 1974-07-31 |
| JPS49132222A (enrdf_load_stackoverflow) | 1974-12-18 |
| DK138727C (enrdf_load_stackoverflow) | 1979-04-02 |
| DE2345917A1 (de) | 1974-04-04 |
| FR2199984B1 (enrdf_load_stackoverflow) | 1976-10-22 |
| CA1025360A (en) | 1978-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1514240A3 (ru) | СПОСОБ ПОЛУЧЕНИЯ СТАБИЛЬНЫХ ЦИКЛОДЕКСТРИН-РОМАШКОВЫХ КОМПЛЕКСОВ, включения | |
| DE69023442T2 (de) | Verwendung einer Cyaninfarbe in einem antitumoralen Mittel. | |
| CN104844631A (zh) | 铜金属配合物及其与人血清白蛋白的复合物以及它们的合成方法及应用 | |
| JP2019537561A (ja) | Ｉｄｈｐの冠状動脈アテローム性硬化症の予防及び治療のための薬物又は健康補助食品の調製における応用 | |
| GB1573965A (en) | Carcinostatic compositions | |
| CN110585238B (zh) | 一种具有协同作用的抗肿瘤药物组合物及其应用 | |
| JP6389958B2 (ja) | 瓦草５環性トリテルペンサポニン類化合物抗腫瘍の薬物用途 | |
| SU584743A3 (ru) | Способ получени производных глюкозы | |
| US8853194B2 (en) | Sterol derivatives and their synthesis and use | |
| CN110538170B (zh) | 玛咖酰胺类化合物或其盐在制备预防或治疗肝纤维化疾病药物的应用 | |
| JPH0160471B2 (enrdf_load_stackoverflow) | ||
| CN104844632B (zh) | 一种铜金属配合物及其与人血清白蛋白的复合物以及它们的合成方法及应用 | |
| PL219734B1 (pl) | Lek przeciwnowotworowy, sposób jego wytwarzania oraz sposób jego stabilizacji | |
| CN105601670B (zh) | 一种铬(iii)配合物及其制备方法和应用 | |
| Richter | Vital staining of bones with madder | |
| CS269719B1 (en) | Platinum cytostatic | |
| KR0139204B1 (ko) | 3-(n-페닐아세틸아미노피페리딘)-2,6-디온의 제조방법 | |
| CA1089365A (en) | Super-saturated isosorbide dinitrate solution process for its production and its use | |
| CN113694055A (zh) | 沉香四醇在制备治疗血管性痴呆疾病的药物中的应用 | |
| CN104402894A (zh) | 3-(1-烷氧乙基)二氢卟吩e6类似物的金属络合物及其制备方法和应用 | |
| CN104557990A (zh) | 氨基多羧酸邻菲罗啉锌配合物的合成及其在抗肿瘤药物中的应用 | |
| RU2238730C1 (ru) | Лекарственный препарат | |
| RU2034564C1 (ru) | Способ получения ингибитора пролиферации опухолевых клеток | |
| KR920010325B1 (ko) | 약용꿀의 제조방법 | |
| Proskouriakoff | Some Salts of Levulinic Acid1 |